Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

TumorNext-Lynch-MMR: a comprehensive next generation sequencing assay for the detection of germline and somatic mutations in genes associated with mismatch repair deficiency and Lynch syndrome.

Gray PN, Tsai P, Chen D, Wu S, Hoo J, Mu W, Li B, Vuong H, Lu HM, Batth N, Willett S, Uyeda L, Shah S, Gau CL, Umali M, Espenschied C, Janicek M, Brown S, Margileth D, Dobrea L, Wagman L, Rana H, Hall MJ, Ross T, Terdiman J, Cullinane C, Ries S, Totten E, Elliott AM.

Oncotarget. 2018 Apr 17;9(29):20304-20322. doi: 10.18632/oncotarget.24854. eCollection 2018 Apr 17.

2.

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.

Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA.

Cancer Discov. 2018 Mar 26. doi: 10.1158/2159-8290.CD-17-0867. [Epub ahead of print]

PMID:
29581176
3.

Synthesis and antiproliferative activity of a series of new platinum and palladium diphosphane complexes.

Cullinane C, Deacon GB, Drago PR, Erven AP, Junk PC, Luu J, Meyer G, Schmitz S, Ott I, Schur J, Webster LK, Klein A.

Dalton Trans. 2018 Feb 6;47(6):1918-1932. doi: 10.1039/c7dt04615d.

PMID:
29340396
4.

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.

Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.

PMID:
29243224
5.

Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.

Darido C, Georgy SR, Cullinane C, Partridge DD, Walker R, Srivastava S, Roslan S, Carpinelli MR, Dworkin S, Pearson RB, Jane SM.

Cell Death Differ. 2017 Dec 13. doi: 10.1038/s41418-017-0032-0. [Epub ahead of print]

PMID:
29238073
6.

Deadly combination: Clostridium septicum and colorectal malignancy.

Cullinane C, Earley H, Tormey S.

BMJ Case Rep. 2017 Dec 2;2017. pii: bcr-2017-222759. doi: 10.1136/bcr-2017-222759.

PMID:
29197851
7.

Mobility and Agility During Locomotion in the Mark III Space Suit.

Cullinane CR, Rhodes RA, Stirling LA.

Aerosp Med Hum Perform. 2017 Jun 1;88(6):589-596. doi: 10.3357/AMHP.4650.2017.

PMID:
28539149
8.

Emergency splenectomy postelective colonoscopy.

Cullinane C, Gudyma J, McArdle G.

BMJ Case Rep. 2017 May 3;2017. pii: bcr-2016-219083. doi: 10.1136/bcr-2016-219083.

PMID:
28473360
9.

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ.

Nat Commun. 2017 Mar 28;8:14844. doi: 10.1038/ncomms14844.

10.

β -[<sup>18</sup>F]Fluoro Azomycin Arabinoside (β -[<sup>18</sup>F]FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors.

Kumar P, Roselt P, Reischl G, Cullinane C, Beiki D, Ehrlichmann W, Binns D, Naimi E, Yang J, Hicks R, Machulla HJ, Wiebe LI.

Curr Radiopharm. 2017;10(2):93-101. doi: 10.2174/1874471010666170313120540.

PMID:
28294075
11.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD.

Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10.

12.

Re: Stillbirth collection by Man et al.

Cox P, Marton T, Hargitai B, Coetzee A, Bowen C, Penman D, Evans M, Gannon C, French P, Cohen M, Holden S, Allotey J, Evans C, Murphy A, Turner K, Cullinane C, Stahlschmidt J, Kokai G, Al Adnani M, Marnerides A, Vadgama B, McPartland J.

Ultrasound Obstet Gynecol. 2017 Feb;49(2):281-282. doi: 10.1002/uog.17380. No abstract available.

13.

Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of αvβ3 Integrin Expression with Gallium-68.

Imberti C, Terry SY, Cullinane C, Clarke F, Cornish GH, Ramakrishnan NK, Roselt P, Cope AP, Hicks RJ, Blower PJ, Ma MT.

Bioconjug Chem. 2017 Feb 15;28(2):481-495. doi: 10.1021/acs.bioconjchem.6b00621. Epub 2016 Dec 14.

14.

A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies.

Rudd SE, Roselt P, Cullinane C, Hicks RJ, Donnelly PS.

Chem Commun (Camb). 2016 Sep 29;52(80):11889-11892.

PMID:
27711378
15.

Correction: A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies.

Rudd SE, Roselt P, Cullinane C, Hicks RJ, Donnelly PS.

Chem Commun (Camb). 2016 Sep 20;52(77):11603.

PMID:
27711356
16.

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

Au-Yeung G, Lang F, Azar WJ, Mitchell C, Jarman KE, Lackovic K, Aziz D, Cullinane C, Pearson RB, Mileshkin L, Rischin D, Karst AM, Drapkin R, Etemadmoghadam D, Bowtell DD.

Clin Cancer Res. 2017 Apr 1;23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. Epub 2016 Sep 23.

17.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

18.

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.

Waldeck K, Cullinane C, Ardley K, Shortt J, Martin B, Tothill RW, Li J, Johnstone RW, McArthur GA, Hicks RJ, Wood PJ.

Int J Cancer. 2016 Jul 1;139(1):194-204. doi: 10.1002/ijc.30056. Epub 2016 Mar 10.

19.

Strand breakage by decay of DNA-bound 124I provides a basis for combined PET imaging and Auger endoradiotherapy.

Lobachevsky P, Clark GR, Pytel PD, Leung B, Skene C, Andrau L, White JM, Karagiannis T, Cullinane C, Lee BQ, Stuchbery A, Kibedi T, Hicks RJ, Martin RF.

Int J Radiat Biol. 2016 Nov;92(11):686-697. Epub 2016 Feb 23.

PMID:
26902391
20.

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW.

Cancer Res. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877. Epub 2015 Dec 1.

21.

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, Sanij E, Kang J, Drygin D, O'Brien S, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Cancer Discov. 2016 Jan;6(1):59-70. doi: 10.1158/2159-8290.CD-14-0673. Epub 2015 Oct 21.

22.

Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate.

Ma MT, Cullinane C, Waldeck K, Roselt P, Hicks RJ, Blower PJ.

EJNMMI Res. 2015 Dec;5(1):52. doi: 10.1186/s13550-015-0131-1. Epub 2015 Oct 9.

23.

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, Madore J, Mann GJ, Hayward NK, McArthur GA, Filipp FV, Hersey P.

Oncotarget. 2015 Sep 29;6(29):27023-36. doi: 10.18632/oncotarget.4809.

24.

New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with (68)Ga(3.).

Ma MT, Cullinane C, Imberti C, Baguña Torres J, Terry SY, Roselt P, Hicks RJ, Blower PJ.

Bioconjug Chem. 2016 Feb 17;27(2):309-18. doi: 10.1021/acs.bioconjchem.5b00335. Epub 2015 Sep 2.

25.

Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma.

Broadhead ML, Lokmic Z, Tan ML, Stevenson A, Binns DS, Cullinane C, Hicks RJ, Choong PF, Myers DE.

Front Surg. 2015 Aug 3;2:36. doi: 10.3389/fsurg.2015.00036. eCollection 2015.

26.

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.

Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, Haupt S, Haupt Y, Wiman KG, Duong CP, Clemons NJ, Phillips WA.

Gut. 2015 Oct;64(10):1506-16. doi: 10.1136/gutjnl-2015-309770. Epub 2015 Jul 17.

PMID:
26187504
27.

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling.

Heinemann A, Cullinane C, De Paoli-Iseppi R, Wilmott JS, Gunatilake D, Madore J, Strbenac D, Yang JY, Gowrishankar K, Tiffen JC, Prinjha RK, Smithers N, McArthur GA, Hersey P, Gallagher SJ.

Oncotarget. 2015 Aug 28;6(25):21507-21.

28.

Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts.

Read M, Liu D, Duong CP, Cullinane C, Murray WK, Fennell CM, Shortt J, Westerman D, Burton P, Clemons NJ, Phillips WA.

Ann Surg Oncol. 2016 Jan;23(1):305-11. doi: 10.1245/s10434-015-4425-3. Epub 2015 Feb 18.

PMID:
25691278
29.

IV access service provision.

Harker H, Porter C, Smith E, Cullinane C.

Br J Nurs. 2015 Jan 22-Feb 11;24(2):S12-3. doi: 10.12968/bjon.2015.24.Sup2.S12. No abstract available.

PMID:
25616124
30.

Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.

Kinross KM, Montgomery KG, Mangiafico SP, Hare LM, Kleinschmidt M, Bywater MJ, Poulton IJ, Vrahnas C, Henneicke H, Malaterre J, Waring PM, Cullinane C, Sims NA, McArthur GA, Andrikopoulos S, Phillips WA.

FASEB J. 2015 Apr;29(4):1426-34. doi: 10.1096/fj.14-262782. Epub 2014 Dec 30.

PMID:
25550458
31.

Measuring apoptosis in mammals in vivo.

Newbold A, Martin BP, Cullinane C, Bots M.

Cold Spring Harb Protoc. 2014 Nov 3;2014(11):1125-7. doi: 10.1101/pdb.top070417.

PMID:
25368316
32.

Detection of apoptotic cells using propidium iodide staining.

Newbold A, Martin BP, Cullinane C, Bots M.

Cold Spring Harb Protoc. 2014 Nov 3;2014(11):1202-6. doi: 10.1101/pdb.prot082545.

PMID:
25368311
33.

Detection of apoptotic cells using immunohistochemistry.

Newbold A, Martin BP, Cullinane C, Bots M.

Cold Spring Harb Protoc. 2014 Nov 3;2014(11):1196-201. doi: 10.1101/pdb.prot082537.

PMID:
25368310
34.

Bifunctional (64)Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography.

Paterson BM, Buncic G, McInnes LE, Roselt P, Cullinane C, Binns DS, Jeffery CM, Price RI, Hicks RJ, Donnelly PS.

Dalton Trans. 2015 Mar 21;44(11):4901-9. doi: 10.1039/c4dt02983f.

PMID:
25351329
35.

Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in solid tumors.

Newbold A, Martin BP, Cullinane C, Bots M.

Cold Spring Harb Protoc. 2014 Oct 1;2014(10):pdb.prot082529. doi: 10.1101/pdb.prot082529.

PMID:
25275109
36.

Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in hematological tumors.

Newbold A, Martin BP, Cullinane C, Bots M.

Cold Spring Harb Protoc. 2014 Oct 1;2014(10):pdb.prot082511. doi: 10.1101/pdb.prot082511.

PMID:
25275108
37.

Truncal myxoid Dermatofibrosarcoma Protuberans in a 11-month old child.

Kolar MK, Cullinane C, Bourke G.

J Plast Reconstr Aesthet Surg. 2014 Nov;67(11):e282-3. doi: 10.1016/j.bjps.2014.07.037. Epub 2014 Aug 4. No abstract available.

PMID:
25163850
38.

Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.

Lewin J, Cullinane C, Akhurst T, Waldeck K, Watkins DN, Rao A, Eu P, Mileshkin L, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):25-32. doi: 10.1007/s00259-014-2888-2. Epub 2014 Aug 16.

PMID:
25125202
39.

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Gallagher SJ, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, Jin L, Pupo G, Cullinane C, McArthur GA, Tummino PJ, Rizos H, Hersey P.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1126-37. doi: 10.1111/pcmr.12282. Epub 2014 Jul 3.

PMID:
24924589
40.

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

Gallagher SJ, Mijatov B, Gunatilake D, Tiffen JC, Gowrishankar K, Jin L, Pupo GM, Cullinane C, Prinjha RK, Smithers N, McArthur GA, Rizos H, Hersey P.

J Invest Dermatol. 2014 Nov;134(11):2795-2805. doi: 10.1038/jid.2014.243. Epub 2014 Jun 6.

41.

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, Pearson RB, Christensen JG, Randolph S, McArthur GA, Sheppard KE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):590-600. doi: 10.1111/pcmr.12228. Epub 2014 Mar 6.

PMID:
24495407
42.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.

43.

Rapidly enlarging eyelid mass.

Falzon K, Kalantzis G, Chang B, Cullinane C, Long V.

J Pediatr. 2014 Apr;164(4):937-8. doi: 10.1016/j.jpeds.2013.12.002. Epub 2014 Jan 10. No abstract available.

PMID:
24418470
44.

Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells.

Azad A, Bukczynska P, Jackson S, Haupt Y, Cullinane C, McArthur GA, Solomon B.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):385-94. doi: 10.1016/j.ijrobp.2013.10.043. Erratum in: Int J Radiat Oncol Biol Phys. 2014 May;89(1):226. Haput, Ygal [corrected to Haupt, Ygal].

PMID:
24411611
45.

Twenty four-hour helpline access to expert management advice for food-allergy-triggered anaphylaxis in infants, children and young people: a pragmatic, randomized controlled trial.

Kelleher MM, Dunngalvin A, Sheikh A, Cullinane C, Fitzsimons J, Hourihane JO.

Allergy. 2013 Dec;68(12):1598-604. doi: 10.1111/all.12310.

PMID:
24410783
46.

Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.

Cullinane C, Waldeck KL, Binns D, Bogatyreva E, Bradley DP, de Jong R, McArthur GA, Hicks RJ.

Nucl Med Biol. 2014 Feb;41(2):148-54. doi: 10.1016/j.nucmedbio.2013.11.001. Epub 2013 Nov 15.

PMID:
24332383
47.

Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.

Elsum IA, Yates LL, Pearson HB, Phesse TJ, Long F, O'Donoghue R, Ernst M, Cullinane C, Humbert PO.

Oncogene. 2014 Nov 27;33(48):5523-33. doi: 10.1038/onc.2013.498. Epub 2013 Nov 25.

PMID:
24276238
48.

Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation.

Kansara M, Leong HS, Lin DM, Popkiss S, Pang P, Garsed DW, Walkley CR, Cullinane C, Ellul J, Haynes NM, Hicks R, Kuijjer ML, Cleton-Jansen AM, Hinds PW, Smyth MJ, Thomas DM.

J Clin Invest. 2013 Dec;123(12):5351-60. doi: 10.1172/JCI70559. Epub 2013 Nov 15.

49.

PET imaging of tumours with a 64Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate.

Paterson BM, Roselt P, Denoyer D, Cullinane C, Binns D, Noonan W, Jeffery CM, Price RI, White JM, Hicks RJ, Donnelly PS.

Dalton Trans. 2014 Jan 21;43(3):1386-96. doi: 10.1039/c3dt52647j. Epub 2013 Nov 7.

PMID:
24202174
50.

Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.

Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW.

Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3.

Supplemental Content

Loading ...
Support Center